Chiropractors in Cicero, IN Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Teresa Ann Lewis, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 209 S Peru St, Cicero, IN 46034 Phone: 317-984-3578 Fax: 317-984-3410 |
 Dr. John M Lewis, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 209 S Peru St, Cicero, IN 46034 Phone: 317-984-3578 Fax: 317-984-3410 |
 Cicero Chiropractic Inc. Chiropractor Medicare: Medicare Enrolled Practice Location: 209 S Peru St, Cicero, IN 46034 Phone: 317-984-3578 Fax: 317-984-3410 |
Richard F Helminiak Ii, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 940 Morse Landing Dr, Cicero, IN 46034 Phone: 812-208-0463 |
News Archive
TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
In jobs bill, Democrats push to include extension of COBRA benefits, Medicare 'doc fix'
The New York Times reports that Democrats are trying to address some health coverage considerations in their jobs bill even as they grasp "for ideas to keep alive their health care legislation." Negotiators on the Senate Finance Committee may be close to a jobs agreement. "Democrats were also pushing to include an extension of unemployment benefits and of health care coverage for those out of work." Also under discussion was the possibility of "attaching other initiatives, including a provision to prevent a steep cut in Medicare payment rates for doctors" (Hulse and Zeleny, 2/4).
Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
FDA to beef up monitoring of imports
As Food and Drug Administration (FDA) commissioner, Dr. Margaret A. Hamburg has been trying to correct inadequately controlled imported food and drugs overwhelming her organization's ability to monitor them.
iWorx launches a family of cardiovascular research products
iWorx, a developer of advanced physiology research and teaching tools, has launched a family of cardiovascular research products used to assess cardiac performance and hemodynamics, both in vivo and in vitro.
› Verified 1 days ago